WASHINGTON — The Food and Drug Administration should enhance information sharing, advance the regulatory science needed to evaluate rare disease drugs, improve engagement with people with rare ...
Brad Reisfeld does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results